The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies

Headache

Volumn 55, Issue 1, 2015, Pages 3-20

  Marmura, Michael J ^a   Silberstein, Stephen D ^b   Schwedt, Todd J ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

acute treatment; clinical trial; episodic migraine; migraine; pharmacology

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CODEINE PHOSPHATE PLUS PARACETAMOL; ALMOTRIPTAN; BUTORPHANOL; CHLORPROMAZINE; DICLOFENAC; DIHYDROERGOTAMINE; DROPERIDOL; ELETRIPTAN; ERGOTAMINE; FLURBIPROFEN; FROVATRIPTAN; IBUPROFEN; ISOMETHEPTENE; KETOPROFEN; KETOROLAC; MAGNESIUM; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NARATRIPTAN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE DERIVATIVE; PARACETAMOL; PARACETAMOL PLUS TRAMADOL; PROCHLORPERAZINE; RIZATRIPTAN; SUMATRIPTAN; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN; ANTIINFLAMMATORY AGENT; SEROTONIN AGONIST;

ADULTHOOD; ARTICLE; DRUG EFFICACY; DRUG INDICATION; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL SOCIETY; MIGRAINE; MIGRAINE WITH AURA; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; UNITED STATES; ADULT; MIGRAINE DISORDERS; STANDARDS; STATISTICS AND NUMERICAL DATA;

ADULT; ANTI-INFLAMMATORY AGENTS; HUMANS; MIGRAINE DISORDERS; SEROTONIN RECEPTOR AGONISTS; SOCIETIES, MEDICAL;

EID: 84921392169     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12499     Document Type: Article

References (66)

1. Stewart WF, Lipton RB, Celentano DD, Reed ML,. Prevalence of migraine headache in the United States. Relation to age, income, race and other sociodemographic factors. JAMA. 1992; 267: 64-69.
2. Headache Classification of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33: 627-808.
3. Holland S, Silberstein SD, Freitag F, Dodick DW, Argoff C, Ashman E,. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78: 1346-1353.
4. Silberstein SD,. Practice parameter-Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards Subcommittee of the American Academy of Neurology for the United States Headache Consortium. Neurology. 2000; 55: 754-762.
5. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in migraine: Third edition. A guide for investigators. Cephalalgia. 2012; 32: 6-38.
6. American Academy of Neurology. Clinical Practice Guideline Process Manual. St. Paul, MN: The American Academy of Neurology; 2011.
7. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press; 2011.
8. Dahlof C, Tfelt-Hansen P, Massiou H, Fazekas A,. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology. 2001; 57: 1811-1817.
9. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia. 2000; 20: 488-496.
10. Goadsby PJ, Zanchin G, Geraud G, et al. Early vs non-early intervention in acute migraine-"Act when Mild (AwM)." A double-blind, placebo controlled trial of almotriptan. Cephalalgia. 2008; 28: 383-391.
11. Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: Results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache. 2007; 47: 189-198.
12. Diener HC, Gendolla A, Gebert I, Beneke M,. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache. 2005; 45: 874-882.
13. Eletriptan Steering Committee. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia. 2002; 22: 416-423.
14. Sheftell F, Ryan R, Pitman V,. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: A multicenter, double-blind, placebo-controlled study conducted in the United States. Headache. 2003; 43: 202-213.
15. Stark R, Dahlof C, Haughie S, Hettiarachchi J,. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: Results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia. 2002; 22: 23-32.
16. Brandes JL, Kudrow D, Cady R, Tiseo PJ, Sun W, Sikes CR,. Eletriptan in the early treatment of acute migraine: Influence of pain intensity and time of dosing. Cephalalgia. 2005; 25: 735-742.
17. Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia. 2003; 23: 463-471.
18. Olesen J, Diener HC, Schoenen J, Hettiarachchi J,. No effect of eletriptan administration during the aura phase of migraine. Eur J Neurol. 2004; 11: 671-677.
19. Rapoport A, Ryan R, Goldstein J, Keywood C,. Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache. 2002; 42 (Suppl. 2): S74-S83.
20. Goldstein J, Keywood C,. Frovatriptan for the acute treatment of migraine: A dose-finding study. Headache. 2002; 42: 41-48.
21. Cady R, Elkind A, Goldstein J, Keywood C,. Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Curr Med Res Opin. 2004; 20: 1465-1472.
22. Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C,. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur J Neurol. 2005; 12: 774-781.
23. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia. 1999; 19: 525-530.
24. Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache. 2006; 46: 914-924.
25. Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: Two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia. 2007; 27: 414-421.
26. Seeburger JL, Cady RK, Winner P, et al. Rizatriptan for treatment of acute migraine in patients taking topiramate for migraine prophylaxis. Headache. 2012; 52: 57-67.
27. Seeburger JL, Taylor FR, Friedman D, et al. Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. Cephalalgia. 2011; 31: 786-796.
28. Carpay J, Schoenen J, Ahmad F, Kinrade F, Boswell D,. Efficacy and tolerability of sumatriptan tablets in a fast-disintegrating, rapid-release formulation for the acute treatment of migraine: Results of a multicenter, randomized, placebo-controlled study. Clin Ther. 2004; 26: 214-223.
29. Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS,. Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther. 2005; 27: 407-417.
30. Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006; 28: 517-526.
31. Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M,. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012; 52: 1402-1410.
32. Djupesland PG, Docekal P,. Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: A randomised, placebo-controlled study. Cephalalgia. 2010; 30: 933-942.
33. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA. 2007; 297: 1443-1454.
34. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache. 2009; 49: 971-982.
35. Loder E, Freitag FG, Adelman J, Pearlmand S, bu-Shakra S,. Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: Results of a large double-blind placebo-controlled trial. Curr Med Res Opin. 2005; 21: 381-389.
36. Spierings EL, Rapoport AM, Dodick DW, Charlesworth B,. Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs. 2004; 18: 1133-1141.
37. Dodick DW, Brandes J, Elkind A, Mathew N, Rodichok L,. Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: A randomised, double-blind, placebo-controlled study. CNS Drugs. 2005; 19: 125-136.
38. Gawel M, Aschoff J, May A, Charlesworth BR,. Zolmitriptan 5 mg nasal spray: Efficacy and onset of action in the acute treatment of migraine-Results from phase 1 of the REALIZE study. Headache. 2005; 45: 7-16.
39. Aurora SK, Rozen TD, Kori SH, Shrewsbury SB,. A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine. Headache. 2009; 49: 826-837.
40. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: A randomized, controlled study in the acute treatment of migraine. Headache. 2011; 51: 507-517.
41. Peatfield RC, Petty RG, Rose FC,. Double blind comparison of mefenamic acid and acetaminophen (paracetamol) in migraine. Cephalalgia. 1983; 3: 129-134.
42. Karabetsos A, Karachalios G, Bourlinou P, Reppa A, Koutri R, Fotiadou A,. Ketoprofen versus paracetamol in the treatment of acute migraine. Headache. 1997; 37: 12-14.
43. Lipton RB, Baggish JS, Stewart WF, Codispoti M,. Efficacy and safety of acetaminophen in the treatment of migraine: Results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med. 2000; 160: 3486-3492.
44. Leinisch E, Evers S, Kaempfe N, et al. Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks: A double-blind, placebo-controlled parallel group multicenter study. Pain. 2005; 117: 396-400.
45. Bigal ME, Bordini CA, Speciali JG,. Intravenous chlorpromazine in the emergency department treatment of migraines: A randomized controlled trial. J Emerg Med. 2002; 23: 141-148.
46. Silberstein SD, Young WB, Mendizabal JE, Rothrock JF, Alam AS,. Acute migraine treatment with droperidol: A randomized, double-blind, placebo-controlled trial. Neurology. 2003; 60: 315-321.
47. Gobel H, Heinze A, Niederberger U, Witt T, Zumbroich V,. Efficacy of phenazone in the treatment of acute migraine attacks: A double-blind, placebo-controlled, randomized study. Cephalalgia. 2004; 24: 888-893.
48. MacGregor EA, Dowson A, Davies PT,. Mouth-dispersible aspirin in the treatment of migraine: A placebo-controlled study. Headache. 2002; 42: 249-255.
49. Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN,. Aspirin is efficacious for the treatment of acute migraine. Headache. 2005; 45: 283-292.
50. Dahlof C, Bjorkman R,. Diclofenac-K (50 and 100 mg) and placebo in the acute treatment of migraine. Cephalalgia. 1993; 13: 117-123.
51. Massiou H, Serrurier D, Lasserre O, Bousser MG,. Effectiveness of oral diclofenac in the acute treatment of common migraine attacks: A double-blind study versus placebo. Cephalalgia. 1991; 11: 59-63.
52. The Diclofenac-K-Sumatriptan Migraine Study Group. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac/potassium, in comparison to oral sumatriptan and placebo. Cephalalgia. 1999; 19: 232-240.
53. Vecsei L, Gallacchi G, Sagi I, et al. Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study. Cephalalgia. 2007; 27: 29-34.
54. Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: A randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia. 2006; 26: 537-547.
55. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: Results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia. 2010; 30: 1336-1345.
56. Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB,. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache. 2001; 41: 665-679.
57. Pfaffenrath V, Fenzl E, Bregman D, Farkkila M,. Intranasal ketorolac tromethamine (SPRIX(R)) containing 6% of lidocaine (ROX-828) for acute treatment of migraine: Safety and efficacy data from a phase II clinical trial. Cephalalgia. 2012; 32: 766-777.
58. Silberstein SD, Freitag FG, Rozen TD, et al. Tramadol/acetaminophen for the treatment of acute migraine pain: Findings of a randomized, placebo-controlled trial. Headache. 2005; 45: 1317-1327.
59. Alemdar M, Pekdemir M, Selekler HM,. Single-dose intravenous tramadol for acute migraine pain in adults: A single-blind, prospective, randomized, placebo-controlled clinical trial. Clin Ther. 2007; 29: 1441-1447.
60. Levy MJ, Matharu MS, Bhola R, Meeran K, Goadsby PJ,. Octreotide is not effective in the acute treatment of migraine. Cephalalgia. 2005; 25: 48-55.
61. Bigal ME, Bordini CA, Tepper SJ, Speciali JG,. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebo-controlled study. Cephalalgia. 2002; 22: 345-353.
62. Cete Y, Dora B, Ertan C, Ozdemir C, Oktay C,. A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs metoclopramide in the management of acute migraine attacks in the emergency department. Cephalalgia. 2005; 25: 199-204.
63. Stillman MJ, Zajac D, Rybicki LA,. Treatment of primary headache disorders with intravenous valproate: Initial outpatient experience. Headache. 2004; 44: 65-69.
64. Waberzinek G, Markova J, Mastik J,. Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. Neuro Endocrinol Lett. 2007; 28: 59-64.
65. Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S,. Practice parameter: Pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology. 2004; 63: 2215-2224.
66. Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J,. Zolmitriptan oral tablet in migraine treatment: High placebo responses in adolescents. Headache. 2006; 46: 101-109.